LQZ-7F

• Description :

  LQZ-7F, a survivin dimerization inhibitor, induces spontaneous apoptosis and synergizes with Docetaxel in prostate cancer cells. LQZ-7F dose-dependently inhibits survival of both PC-3 and C4-2 cells with IC50s of 2.99 and 2.47 μM, respectively[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H320

• Target :

  Apoptosis; Survivin

• Type :

  Reference compound

• Related Pathways :

  Apoptosis

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/lqz-7f.html

• Purity :

  97.44

• Solubility :

  DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(C1=NON=C1N)N/N=C2C3=C(C4=NC5=NON=C5N=C4\2)C=CC=C3

• Molecular Formula :

  C14H7N9O3

• Molecular Weight :

  349.26

• Precautions :

  H315, H319, H320

• References & Citations :

  [1]Robert Peery, et al. A novel survivin dimerization inhibitor without a labile hydrazone linker induces spontaneous apoptosis and synergizes with docetaxel in prostate cancer cells. Bioorg Med Chem. 2022 Jul 1;65:116761.|[2]Qi Jing, et al. Effective Targeting of the Survivin Dimerization Interface with Small-Molecule Inhibitors. Cancer Research. 2016 Jan. 76 (2) :453-462.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [354543-09-2]